Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a clinical-stage biopharmaceutical company whose news flow centers on the development of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, and related immunomodulation programs. Company announcements highlight progress in neuroinflammatory and neurodegenerative indications, including non-active secondary progressive multiple sclerosis, early Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS).
News about Tiziana often covers key clinical milestones. Recent releases describe dosing of patients in a Phase 2 randomized, placebo-controlled trial of intranasal foralumab in early Alzheimer’s disease, including evaluation as monotherapy and in combination with FDA-approved anti-amyloid therapies lecanemab and donanemab. Other updates report on the Expanded Access Program in non-active secondary progressive multiple sclerosis and the acceptance of the company’s ALS Phase 2 trial into the ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS.
Investors following TLSA news can also expect regulatory and safety updates, such as the submission of Development Safety Update Reports to the U.S. Food and Drug Administration, which summarize cumulative exposure and safety findings for intranasal foralumab. Corporate and capital markets news includes insider share purchases by senior leadership, decisions regarding proposed public offerings, and participation in industry conferences like BIO-Europe, the Jefferies London Healthcare Conference, and neuroscience-focused forums.
This news page aggregates these company-issued press releases and related coverage, giving readers a centralized view of Tiziana’s clinical progress, regulatory interactions, strategic initiatives such as the planned spinout of IL-6 asset TZLS-501, and visibility events like ringing the Nasdaq Closing Bell. Users interested in TLSA can review this feed to monitor how Tiziana’s immunotherapy and drug delivery programs evolve over time.
Tiziana Life Sciences (Nasdaq: TLSA) announced a collaboration with Parexel to conduct a global Phase 1b/2 trial using take-home capsules of Foralumab, the only fully human anti-CD3 monoclonal antibody, for moderate to severe Crohn's Disease.
This study will enroll 60 patients across the U.S. and Europe, aiming to evaluate safety and efficacy. The Crohn's Disease therapeutics market is projected to reach $4.7 billion by 2025, emphasizing the potential of Foralumab as a safer alternative to intravenous therapies, improving patient compliance and outcomes.
Tiziana Life Sciences (Nasdaq: TLSA) announced a clinical study for nasally administered Foralumab in COVID-19 patients in Brazil, starting November 3, 2020. This collaboration includes Harvard Medical School and aims to address Brazil's critical COVID-19 situation, with nearly 5.5 million cases reported. The trial seeks to demonstrate the drug's potential to enhance nasal immunity and suppress inflammation associated with the disease. Clinical data is anticipated by year-end, following a patent filed for its use in COVID-19 treatment.
Tiziana Life Sciences plc (Nasdaq: TLSA) has announced the timetable for the demerger of Accustem Sciences Limited, which involves spinning off its StemPrintER technology for predicting breast cancer recurrence. The StemPrintER demonstrated superior accuracy over Oncotype DX in predicting the 10-year risk for over 800 ER+/HER2-breast cancer patients. Key dates for the demerger include October 27, 2020, for court approval, and November 6, 2020, as the record date for ADR holders. A new ADR program for Accustem is in the works, with expected timelines aligned for effective registration and trading.
Tiziana Life Sciences (TLSA) announced that all resolutions were passed at the General Meeting on October 2, 2020. Key dates regarding the demerger of Accustem Sciences Limited, which will re-register as Accustem Sciences Plc, are outlined, including a court hearing on October 14 and completion of the demerger on October 30. The company received clearance from HMRC confirming that the demerger is for bona fide commercial reasons, ensuring shareholders will not face capital gains tax liabilities from receiving Accustem shares. Full voting results will be available on the company’s website.
Tiziana Life Sciences plc (NASDAQ: TLSA) announced an interview with CEO Dr. Kunwar Shailubhai, set to air on The RedChip Money Report on September 27, 2020. The discussion will cover the spinout of StemPrintER into a new entity, Accustem Sciences, and the upcoming clinical study of Foralumab for COVID-19 in Brazil. Tiziana is also advancing phase 2 studies for the orally and nasally administered Foralumab, targeting various autoimmune diseases, while working on an anti-IL6R mAb for COVID-19 treatment.
Tiziana Life Sciences (NASDAQ: TLSA) has announced a new analyst research note published by H.C. Wainwright & Co., available on their website. The company focuses on developing novel therapies for oncology, inflammation, and infectious diseases. Tiziana is advancing its pipeline, including phase 2 studies for foralumab, a human anti-CD3 monoclonal antibody targeting Crohn’s Disease and multiple sclerosis. They are also accelerating development of an anti-IL6R monoclonal antibody aimed at treating IL6-induced inflammation, particularly in COVID-19 patients.
Tiziana Life Sciences (NASDAQ: TLSA) announced a collaborative clinical study for the nasal administration of Foralumab in COVID-19 patients in Brazil, aimed at reducing severe symptoms associated with the disease. The study is anticipated to start soon, with preliminary data expected by the end of 2020. Foralumab, a fully human anti-CD3 monoclonal antibody, has shown promise in modulating the immune system, particularly in mitigating cytokine storms that lead to respiratory failure. The innovative approach may significantly impact COVID-19 treatment strategies.
Tiziana Life Sciences (TLSA) announced plans to demerge its StemPrintER asset into Accustem Sciences Limited, an independently listed public company. StemPrintER, a genomic-based assay, is noted for its 40% higher accuracy compared to the Oncotype DX assay for predicting breast cancer recurrence. A shareholder meeting is scheduled for October 2, 2020, with a record date for a 1:1 share dividend on October 30, 2020. Accustem aims for a late Q4 2020 listing on the London Stock Exchange and plans to seek CE Mark approval in November.
Tiziana Life Sciences Plc (LSE: TILS, NASDAQ: TLSA) announced a strategic demerger of its genomics-based business, StemPrintER, into a new company named Accustem Sciences Limited. This decision aims to enhance the commercialization of the StemPrintER platform with an approximate cash reserve of £1 million. The demerger requires court-approved capital reduction and involves a series of meetings and hearings planned for October 2020. Shareholders will receive shares in Accustem based on their holdings in Tiziana during the demerger record time, promoting better focus on both entities' growth strategies.
Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) clarified its filing of a corrected amendment registration statement on Form F-6, which is not for a capital raise but to increase the number of American Depositary Shares (ADSs) for shareholder exchange. Each ADS represents two ordinary shares, and the trend of ordinary shares being exchanged for ADSs has grown recently. The company is also focused on developing drugs for various diseases, including Crohn’s disease and COVID-19, through its novel therapeutic candidates.